Phase 2 multicenter, open-label study (NCT07499102) will evaluate the safety and clinical efficacy of CK0801 Tregs in transfusion-dependent aplastic anemia.

Cellenkos^®, Inc., a clinical-stage biotechnology company, developing allogeneic, tissue-targeted regulatory T cell (Treg) therapies, announced the receipt of U.S. Food and Drug Administration (FDA) clearance to initiate CK0801 Phase 2 clinical trial, for the treatment of aplastic anemia.

Aplastic anemia, a rare and life-threatening blood disorder, continues to present a significant challenge for thousands of patients who fall outside the reach of current standard treatments. Aplastic Anemia develops because of an autoimmune attack on the bone marrow, due to unchecked immune imbalance, resulting from exposure to radiation, toxic chemicals, certain medications, and specific viral infections, though in many cases the cause remains unknown. Characterized by bone marrow's failure to produce essential red blood cells, white blood cells, and platelets, the condition can be fatal within just three months if left untreated. While medical advancements such as intensive immunosuppressive therapy and allogeneic bone marrow transplantation have saved many lives, a stark "unmet need" remains, especially for older Americans > 65 years of age, and patients with minority ethnic background who have difficulty finding a matching donor. These patients are often forced into a lifelong cycle of chronic blood and platelet transfusions. This dependency, coupled with frequent hospitalizations due to severe infections, leads to a drastically diminished quality of life.

"The reality for many aplastic anemia patients is a persistent state of medical fragility," said Simrit Parmar, MD, MSCI, Founder of Cellenkos and Adjunct Faculty at Texas A&M University School of Engineering Medicine (EnMed). "We are seeing a massive gap in care where traditional 'gold standard' treatments simply aren't an option, leaving these individuals in a cycle of supportive care rather than a true recovery."